Faron Pharmaceuticals: Updated BEXMAB data shows increased CR - Redeye

Redeye comments on Faron’s updated data from the Phase I/II BEXMAB trial in frontline high-risk MDS, showing a notable increase in complete remission (CR) rates from 28% to 43% with continued treatment. The deepening of responses over time highlights the durability and clinical relevance of bexmarilimab in combination with azacitidine, particularly when compared to existing standards of care. We believe these results further validate the therapy’s disease-modifying potential and strengthen Faron’s position ahead of its planned Phase III trial and upcoming FDA discussions.

Länk till analysen i sin helhet: https://www.redeye.se/research/1121441/faron-pharmaceuticals-updated-bexmab-data-shows-increased-cr?utm_source=finwire&utm_medium=RSS